Some studies have suggested that thrombopoietin receptor agonists (TPO-RAs), such as eltrombopag or romiplostim, may be safe and effective for the treatment of recurrent and refractory ITP in pregnant women who were unresponsive to IVIG or low-dose corticosteroids (7, 8). Here, TPO is linked to autoimmune thrombocytopenic purpura.